Docetaxel/irinotecan combination chemotherapy in platinum/taxane-refractory and -resistant ovarian cancer: JGOG/WJGOG Intergroup Study

International Journal of Clinical Oncology

Volumn 18, Issue 1, 2013, Pages 126-131

  Ushijima, Kimio ^a   Kamura, Toshiharu ^a   Tamura, Kazuo ^b   Kuzuya, Kazuo ^c   Sugiyama, Toru ^d   Noda, Kiichiro ^e   Ochiai, Kazunori ^f  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b FUKUOKA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c Kuzuya Clinic   (Japan)

^d IWATE MEDICAL UNIVERSITY   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; Irinotecan; Ovarian cancer; Platinum refractory; Platinum resistance; Recurrence

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL PLUS IRINOTECAN; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL; PLATINUM COMPLEX; UNCLASSIFIED DRUG;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EDEMA; FEBRILE NEUTROPENIA; FEMALE; HUMAN; LEUKOPENIA; LIVER DYSFUNCTION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; BRIDGED COMPOUNDS; CAMPTOTHECIN; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; DRUG TOXICITY; FEMALE; HUMANS; JAPAN; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; OVARIAN NEOPLASMS; PLATINUM; TAXOIDS;

EID: 84874112302     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-011-0353-9     Document Type: Article

References (17)

1. Markman M, Rothman R, Hakes T et al (1991) Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:289-393
2. Gore ME, Fryatt I, Wiltshaw E et al (1990) Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds. Gynecol Oncol 36:207-211
3. Ozols RF (2002) Recurrent ovarian cancer: evidence-based treatment. J Clin Oncol 20:1161-1163
4. Gordon AN, Granai CO, Rose PG et al (2000) Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 18:3093-3100
5. Markman M, Webster K, Zanotti K et al (2003) Phase II trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer. Gynecol Oncol 90:593-596
6. Bookman MA, Malmstrom H, Bolis G et al (1998) Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel. J Clin Oncol 16:3345-3352
7. Vasey PA, Atkinson R, Coleman R et al (2001) Docetaxel-carbopltain as first line chemotherapy for epithelial ovarian cancer. Br J Cancer 84:170-178
8. Francis P, Shneider J, Hann J et al (1994) Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. J Clin Oncol 12:2301-2308
9. Kavanagh JJ, Kudelka AP, de Leon CG et al (1996) Phase II study of docetraxel in patients with epithelial ovarian carcinoma refractory to platinum. Clin Cancer Res 2:837-842
10. Sugiyama T, Yakushiji M, Nishida T et al (1998) Irinotecan (CPT-11) combined with cisplatin in patients with refractory or recurrent ovarian cancer. Cancer Lett 128:211-218
11. Rustin GJ, Quinn M, Thigpen T et al (2004) New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst 96:487-488
12. Markman M, Hall J, Spitz D et al (2002) Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer. J Clin Oncol 20:2365-2369
13. Vershragen CF, Sittisomwong T, Kudelka AP et al (2000) Docetaxel for patients with paclitaxel-resistant Mullerian carcinoma. J Clin Oncol 18:2733-2739
14. Polyzos A, Kosmas C, Toufex H et al (2005) Docetaxel in combination with irinotecan (CPT-11) in platinum-resistant paclitaxel-pretreated ovarian cancer. Anticancer Res 25:3559-3564
15. Petru E, Angleitner-Boubenizek, Reinthaller A et al (2006) Weekly docetaxel and irinotecan in platinum-refractory and resistant ovarian cancer: a phase II study of the Austrian AGO:0152. Int J Gynecol Cancer 16(Suppl 3):643
16. O'Malley DM, Azodi M, Makkenchery et al (2005) Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian carcinoma. Gynecol Oncol 98:242-248
17. Mutch DG, Orland M, Goss T et al (2007) Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer. J Clin Oncol 25:2811-2818